Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sikarin PCLBKK:SKR-R -0.63%90 Cash-to-Debt is 2.61 as of Jun. 2026, which is 1143% above its 10-year median of 0.21. GuruFocus rates BKK:SKR-R with a GF Score™ of 90/100 and a GF Value™ of ฿8.11 (Fairly Valued). The stock has 5 warning signs investors should review. Among 660 Healthcare Providers & Services companies, Sikarin PCL ranks better than 70.3% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Sikarin PCL's cash to debt ratio for the quarter that ended in Jun. 2026 was 2.61.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Sikarin PCLcould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Sikarin PCL's Cash-to-Debt or its related term are showing as below:
BKK:SKR-R'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02 Med: 0.21 Max: 2.84
Current: 2.61
During the past 13 years, Sikarin PCL's highest Cash to Debt Ratio was 2.84. The lowest was 0.02. And the median was 0.21.
BKK:SKR-R's Cash-to-Debt is ranked better than 70.3% of 660
companies
in the Healthcare Providers & Services industry
Industry Median: 0.755
vs BKK:SKR-R: 2.61
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Sikarin PCL Cash-to-Debt Related Terms
Sikarin PCL Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Sikarin PCL's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
BKK:SKR-R vs HCA, THC, DVA: Cash-to-Debt Comparison
For the Medical Care Facilities subindustry, Sikarin PCL's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sikarin PCL Cash-to-Debt vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sikarin PCL's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Sikarin PCL's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sikarin PCL (BKK:SKR-R) has a Cash-to-Debt of 2.61 as of Jun. 2026. This is 1143% above median its historical median of 0.21. Over the past decade, Sikarin PCL's Cash-to-Debt has ranged from 0.02 to 2.84. According to the industry distribution chart, Sikarin PCL ranks #196 out of 660 companies in the Healthcare Providers & Services industry, placing it in the top 29.7%.
Is Sikarin PCL's Cash-to-Debt too high?
Sikarin PCL's current Cash-to-Debt of 2.61 is 1143% above median its 10-year median of 0.21. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 2.84. The Healthcare Providers & Services industry median Cash-to-Debt is 0.76. Sikarin PCL's value of 2.61 is 245.7% above this industry median. Based on the distribution chart, Sikarin PCL ranks #196 out of 660 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Sikarin PCL has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sikarin PCL's Cash-to-Debt compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Sikarin PCL ranks #196 out of 660 companies for Cash-to-Debt. This puts Sikarin PCL in the upper half of its industry. The industry median Cash-to-Debt is 0.76. Sikarin PCL's value of 2.61 is 245.7% above this benchmark. Historically, Sikarin PCL's own Cash-to-Debt has ranged from 0.02 to 2.84 over the past decade. While the company's 10-year median is 0.21 vs. the industry median of 0.76, Sikarin PCL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Healthcare Providers & Services company?
The median Cash-to-Debt among Healthcare Providers & Services companies is 0.76, based on 660 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sikarin PCL's current Cash-to-Debt of 2.61 is 245.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median Cash-to-Debt is 0.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sikarin PCL's current Cash-to-Debt is 2.61, which is 1143% above median its own 10-year median of 0.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sikarin PCL stock overvalued right now?
Based on GuruFocus' analysis, Sikarin PCL (BKK:SKR-R) is currently considered Fairly Valued. The stock's GF Value™ is ฿8.11, compared to a current price of ฿7.85 — trading 3.2% below its estimated fair value. The current Cash-to-Debt is 2.61, which is 1143% above median its 10-year median of 0.21 and 245.7% above the Healthcare Providers & Services industry median of 0.76. Sikarin PCL's overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Sikarin PCL (BKK:SKR-R), the current Cash-to-Debt is 2.61 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sikarin PCL (BKK:SKR-R) Overvalued in 2026?
Based on GuruFocus' analysis, Sikarin PCL stock appears to be undervalued.
The current stock price of ฿7.85 is trading 3.2% below its estimated GF Value™ of ฿8.11.
GuruFocus considers Sikarin PCL to be Fairly Valued.
Key valuation signals for BKK:SKR-R:
Cash-to-Debt: 2.61 (1143% above median its 10-year median of 0.21)
GF Value™: ฿8.11 vs. price of ฿7.85 (3.2% below fair value)
Industry Position: 245.7% above the Healthcare Providers & Services median (#196 of 660)
No single metric tells the full story. See the BKK:SKR-R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SSikarin PCL provides general healthcare services and operates under the social security system. The Group has one main operating segment, which is providing healthcare services through private hospitals and hospitals affiliated with the social security system. The Group operates in a single geographical area, which is Thailand. Its services include medical centers, a pediatric center, a women's institute, a radiology center, a neurology center, a rehabilitation center, and an orthopedic center.
90GF Score
Get the complete analysis for BKK:SKR-R
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:SKR-R has been successfully added to your 
